Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate

This phase 1 study characterized the effect of multiple doses of upadacitinib, an oral Janus kinase 1 selective inhibitor, on the pharmacokinetics of the cytochrome P450 (CYP) 2B6 substrate bupropion. Healthy subjects (n = 22) received a single oral dose of bupropion 150 mg alone (study period 1) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed‐Eslam F., Minocha, Mukul, Trueman, Sheryl, Feng, Tian, Enejosa, Jeffrey, Fisniku, Ogert, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984436/
https://www.ncbi.nlm.nih.gov/pubmed/32648334
http://dx.doi.org/10.1002/cpdd.844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984436/
https://www.ncbi.nlm.nih.gov/pubmed/32648334
http://dx.doi.org/10.1002/cpdd.844

Ejemplares similares